subscribeSubscribe
Novartis Presents Latest Phase III Fabhalta Data

Novartis Presents Latest Phase III Fabhalta Data
PRESS RELEASE
25 May 2024
Share Share
Novartis Fabhalta® C3G Phase 3: 35.1% Proteinuria Reduction Vs Placebo

Novartis Fabhalta® C3G Phase 3: 35.1% Proteinuria Reduction Vs Placebo
GLOBENEWSWIRE
25 May 2024
Share Share
Novartis touts trial win, nabs priority review for Fabhalta

Novartis touts trial win, nabs priority review for Fabhalta
Eric Sagonowsky FIERCE PHARMA
15 Apr 2024
Share Share
Novartis Fabhalta® Reduces IgAN Proteinuria By 38.3% Vs Placebo

Novartis Fabhalta® Reduces IgAN Proteinuria By 38.3% Vs Placebo
GLOBENEWSWIRE
15 Apr 2024
Share Share
Novartis` Fabhalta wins EU panel`s favour for rare blood disorder

Novartis` Fabhalta wins EU panel`s favour for rare blood disorder
PRESS RELEASE
23 Mar 2024
Share Share
FABHALTA Now Available from Onco360 for the Treatment of PNH

FABHALTA Now Available from Onco360 for the Treatment of PNH
BUSINESSWIRE
20 Dec 2023
Share Share
Novartis shows strong Fabhalta results in another blood disorder

Novartis shows strong Fabhalta results in another blood disorder
FIERCE PHARMA
12 Dec 2023
Share Share
Novartis receives FDA approval for Fabhalta® (iptacopan) for adults with PNH

Novartis receives FDA approval for Fabhalta® (iptacopan) for adults with PNH
PR NEWSWIRE
06 Dec 2023
Share Share
Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix

Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix
GLOBENEWSWIRE
20 Nov 2023
Share Share
Novartis’ iptacopan has ‘faultless’ performance in phase 3

Novartis’ iptacopan has ‘faultless’ performance in phase 3
Gabrielle Masson FIERCE BIOTECH
02 Oct 2023
Share Share